Background: The rise within the variety of most cancers circumstances and the evolution of most cancers care administration have turn out to be a big downside for the French well being care system, thereby making affected person empowerment as a protracted sought-after purpose in continual pathologies. The implementation of an activation measure through the Affected person Activation Measure-13 merchandise (PAM-13) in the midst of most cancers care can probably spotlight the affected person’s wants, with nursing care adapting accordingly.
Goal: The goals of this PARACT (PARAmedical Interventions on Affected person ACTivation) multicentric research have been as follows: (1) consider the implementation of PAM-13 in oncology nursing practices in 5 complete most cancers facilities, (2) determine the obstacles and facilitators to the implementation of PAM-13, and (3) produce suggestions for the dissemination of such interventions in different complete most cancers facilities.
Strategies: This research will comply with the “Attain, Effectiveness, Adoption, Implementation, and Upkeep” framework and can consist of three phases. First, a strong preimplementation evaluation will probably be performed utilizing the Theoretical Domains Framework (TDF) linked to the “Functionality, Alternative, Motivation, and Conduct” mannequin to determine the obstacles and facilitators to implementing new nursing practices in every context. Then, utilizing the Conduct Change Wheel, we are going to personalize a technique for implementing the PAM-13, relying on the specificities of every context, to encourage acceptability by the nursing employees concerned within the mission. This evaluation will probably be carried out through a qualitative research by way of semistructured interviews.
Second, the affected person will probably be included within the research for 12 months, throughout which the affected person care pathway will probably be studied, significantly to gather all related contacts of oncology nurses and different well being professionals concerned within the pathway. The axes of nursing care may even be collected. The first purpose is to implement PAM-13. Secondary elements to be measured are the affected person’s nervousness stage, high quality of life, and well being literacy stage. The oncology nurses will probably be liable for finishing the questionnaires when the affected person is on the hospital for his/her intravenous chemotherapy/immunotherapy remedy. The questionnaires will probably be accomplished thrice in a 12 months: (1) on the time of the affected person’s enrollment, (2) at 6 months, and (3) at 12 months. Third, a postimplementation evaluation will probably be carried out by way of semistructured interviews utilizing the TDF to research the implementation issues at every website.
Outcomes: This research was supported by a grant from the French Ministry of Well being (PHRIP PARACT 2016-0405) and the Lucien Neuwirth Institute of Cancerology of Saint-Etienne, France. Knowledge assortment for this research is ongoing.
Conclusions: This research would enhance the carried out focused nursing interventions in most cancers facilities so {that a} affected person is obtainable a customized most cancers care pathway. Moreover, measuring the extent of activation and the implementation of measures meant to extend such activation may represent a big benefit in decreasing social well being inequalities.
Navigating uncharted waters: Creating a standardized method for evaluating and implementing biosimilar merchandise at a complete most cancers middle
Goal: The processes for formulary implementation and digital well being file (EHR) integration of biosimilar merchandise at a complete most cancers middle are described. Implications for analysis protocols are additionally mentioned.
Abstract: The present literature focuses on sensible concerns for formulary addition of biosimilar merchandise, however there’s a lack of steering on how you can implement the change, significantly throughout the EHR. Earlier than constructing the ordering instruments for biosimilars, the scientific and informatics groups ought to decide the function of biosimilars on the establishment, determine drug-specific product traits that have an effect on treatment construct, and characterize implications of future formulary adjustments or drug shortages. Leveraging an orderable file supplies the power to incorporate logic that maps to a number of merchandise and in addition permits for future implementation of adjustments throughout the treatment file fairly than requiring “swaps” on the remedy protocol stage. The institutional overview board ought to coordinate adjustments in affected analysis protocols and consent kinds and work with principal investigators to amend protocols when obligatory. Pharmacy leaders ought to develop processes to supervise stock in the course of the transition interval and decrease the chance of errors.
Conclusion: The event of a standardized method for evaluating and implementing biosimilar merchandise improves effectivity and collaboration among the many numerous group members liable for the merchandise’ integration into present workflows, together with implications for scientific analysis. Implementing biosimilars for brokers used to deal with most cancers will pose new challenges and require extra concerns. Partial implementation of biosimilars continues to pose a number of challenges within the provision of affected person care.

Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version
Matrix stiffness epigenetically regulates the oncogenic activation of the Sure-associated protein in gastric most cancers
In lots of cancers, tumour development is related to elevated tissue stiffness. But, the mechanisms associating tissue stiffness with tumorigenesis and malignant transformation are unclear. Right here we present that in gastric most cancers cells, the stiffness of the extracellular matrix reversibly regulates the DNA methylation of the promoter area of the mechanosensitive Sure-associated protein (YAP). Reciprocal interactions between YAP and the DNA methylation inhibitors GRHL2, TET2 and KMT2A may cause hypomethylation of the YAP promoter and stiffness-induced oncogenic activation of YAP.
Breast cancer |
BR724 |
TissueArray |
each |
EUR 270 |
Description: Breast cancer, adjacent and adjacent normal tissue array, 66 cases/72 cores |
Breast cancer |
BR725 |
TissueArray |
each |
EUR 270 |
Description: Breast cancer, adjacent and adjacent normal tissue array, 68 cases/72 cores |
Human Cancer Antigen 15-3 (CA 15-3) ELISA Kit |
PRB-5069 |
Cell Biolabs |
96 assays |
EUR 686.4 |
Human Cancer Antigen 15-3 (CA 15-3) ELISA Kit |
PRB-5069-5 |
Cell Biolabs |
5 x 96 assays |
EUR 2739.6 |
Gastrointestinal Cancer Antigen (CA 19-9), antigen grade |
CA1991-N-10 |
Alpha Diagnostics |
10 KU |
EUR 634.8 |
Cancer Antigen 15-3 MUC 1 Antigen (Human Milk) |
VAng-Cr3871-10kU |
Creative Biolabs |
10 kU |
EUR 505.2 |
Description: Cancer Antigen 15-3 MUC 1 Antigen, Host/Source: Human Milk. The purity is detected by salt extraction and delipidization following high speed centrifugation. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2. |
Paraffin Tissue Section - Human Breast Tumor: Lobular carcinoma |
T2235086-3 |
Biochain |
5 slides |
EUR 308.4 |
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
Breast Cancer-Associated Antigen BRCAA1 (BRCAA1) Antibody |
20-abx148333 |
Abbexa |
|
|
|
Breast tumor tissue array (15 of 25) |
BR20821 |
TissueArray |
each |
EUR 474 |
Description: Breast tumor tissue array (15 of 25), including TNM, clinical stage, pathology grade and IHC markers (ER, PR, Her-2) results,104 cases/208 cores |
BSA (Standard Grade) |
30-AB70 |
Fitzgerald |
1 kg |
EUR 1078.8 |
Description: Standard Grade Bovine Serum Albumin (99% pure) |
Cancer Antigen 15-3 MUC 1 Antigen (Human Ascites Fluid) |
VAng-Cr3872-10kU |
Creative Biolabs |
10 kU |
EUR 1363.2 |
Description: Cancer Antigen 15-3 MUC 1 Antigen, Host/Source: Human Ascites Fluid. |
Cancer Antigen CA 15-3 Protein (Human Fluids) |
VAng-Wyb8628-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: CA 15-3 (Breast Cancer Antigen), Cancer antigen from Human Fluids, 12.240 kU/mL. |
Cancer Antigen CA 15-3 Protein (Human Milk) |
VAng-Wyb8631-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: CA 15-3 (Breast Cancer Antigen), Antigen Grade, Cancer antigen from Human Milk, 33.0 kIU/mL. |
Paraffin Tissue Section - Human Brain Tumor: Astrocytoma Grade III |
T2235035-3 |
Biochain |
5 slides |
EUR 308.4 |
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
Breast cancer with cancer adjacent breast tissue array |
BC081116e |
TissueArray |
each |
EUR 306 |
Description: Breast cancer with cancer adjacent breast tissue array, including invasive carcinoma of no special type, breast carcinoma with apocrine differentiation and AT tissue,pat hology grade, IHC (ER/PR/Her-2/Ki67) info, TNM/Stage (AJCC 7th edition), 107 cases/110 cores (core size 1.5mm), replacing BC081116d |
Cancer Antigen 15-3 (CA15-3) (human) ELISA Kit |
K4804-100 |
Biovision |
100 assays |
EUR 1000.8 |
|
Description: Sensitive, Colorimetric Assay |
Breast cancer TMA |
BR602 |
TissueArray |
each |
EUR 270 |
Description: Breast cancer TMA, 3 samples have matched cancer adjacent tissue samples, including pathology grade, TNM and clinical stage (reference AJCC 8th version), 57 cases/60 cores (Core Size 1.5mm), recent tear collections |
Human Cancer PrimaCell4: Breast Tumor Cells Growth Medium |
9-46027 |
CHI Scientific |
5 x 100 ml |
Ask for price |
Breast cancer with matched cancer adjacent breast tissue array |
BR804b |
TissueArray |
each |
EUR 306 |
Description: Breast cancer with matched cancer adjacent breast tissue array, including pathology grade, TNM, clinical stage and IHC markers (ER, PR, Her-2 and Ki67), 40 cases/80 cores, replacing BR804a |
Breast cancer with breast tissue array |
BC08118a |
TissueArray |
each |
EUR 258 |
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 100 cases/100 cores (core size 1.0mm), replacing BC08118 |
Breast cancer with breast tissue array |
BR2085d |
TissueArray |
each |
EUR 546 |
Description: Breast cancer with breast tissue array, including pathology grad, TNM and clinical stage, 188 cases/208 cores, replacing BR2085c |
Breast cancer with breast tissue array |
BR246d |
TissueArray |
each |
EUR 66 |
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage (reference AJCC 7th version), 12 cases/24 cores, replacing BR246c |
Breast cancer with breast tissue array |
BR482 |
TissueArray |
each |
EUR 198 |
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 24 cases/48 cores |
Breast cancer with breast tissue array |
BR720 |
TissueArray |
each |
EUR 270 |
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical satge (reference AJCC 7th version), 72 cases/72 cores |
Breast cancer with breast tissue array |
T087d |
TissueArray |
each |
EUR 66 |
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing T087c |
Breast cancer with breast tissue array |
T088d |
TissueArray |
each |
EUR 66 |
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing T088c |
Human Cancer Tissue Preparation Buffer 4: Breast Tumor Cells |
9-80027 |
CHI Scientific |
1 x 100 ml |
Ask for price |
Breast cancer tissue array |
BR042b |
TissueArray |
each |
EUR 78 |
Description: Breast cancer tissue array, including TNM and pathology grade, 4 cases/4 cores, replacing BR042a |
Breast cancer tissue array |
BR1006a |
TissueArray |
each |
EUR 306 |
Description: Breast cancer tissue array, including pathology grade, TNM and clinical stage, 50 cases/100 cores (core size 1.0mm), replacing BR1006 |
Breast cancer tissue array |
BR1141a |
TissueArray |
each |
EUR 354 |
Description: Breast cancer tissue array, including pathology grade, TNM and clinical stage, IHC marker (ER, PR, HER2 and Ki-67), 114 cases/114 cores, replacing BR1141 |
Breast cancer tissue array |
BR1401 |
TissueArray |
each |
EUR 414 |
Description: Breast cancer tissue array, including TNM and pathology grade, IHC markers ER/PR/Her-2 results, 140 cases/140 cores (core size 1.0mm) |
Breast cancer tissue array |
BR1503f |
TissueArray |
each |
EUR 306 |
Description: Breast cancer tissue array, including TNM and pathology grade, with IHC results of Her-2\ER\PR\Ki67, 75 cases/ 150 cores, replacing BR1503e |
Breast cancer tissue array |
BR1505e |
TissueArray |
each |
EUR 306 |
Description: Breast cancer tissue array, including pathology grade, TNM, clinical stage, and IHC(HER2/ER/PR/Ki67), 75 cases/150 cores, replacing BR1505d |
Breast cancer tissue array |
BR2161 |
TissueArray |
each |
EUR 546 |
Description: Breast cancer tissue array, including TNM and pathology grade, 216 cases/216 cores |
Breast cancer tissue array |
BR247a |
TissueArray |
each |
EUR 234 |
Description: Breast cancer tissue array, with normal tissue, including TNM and pathology grade, IHC marker (HER2), 24 cases/48 cores replacing BR247 |
Breast cancer tissue array |
BR488 |
TissueArray |
each |
EUR 306 |
Description: Breast cancer tissue array, including pathology grade, TNM, clinical stage (AJCC 7th edition), and IHC marker(ER,PR,Her-2), 48 cases/48 cores |
Breast cancer tissue array |
BR501 |
TissueArray |
each |
EUR 270 |
Description: Breast cancer tissue array, including TNM and pathology grade, 50 cases/ 50 cores (core size 1.5mm) |
Breast cancer tissue array |
BR8015a |
TissueArray |
each |
EUR 306 |
Description: Breast cancer tissue array, with adjacent normal tissue and normal tissue, including TNM and pathology grade, 80 cases/80 cores, replacing BC08014 |
Breast cancer tissue array |
BR964 |
TissueArray |
each |
EUR 222 |
Description: Breast cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases/96 cores |
Breast cancer tissue array |
T089c |
TissueArray |
each |
EUR 48 |
Description: Breast cancer tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores(1.5mm), replacing T089b |
Breast cancer and normal tissue array with stage and grade info |
BR8012 |
TissueArray |
each |
EUR 306 |
Description: Breast cancer and normal tissue array with stage and grade info, 40 cases/80 cores, replaced by BR8014 |
Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit |
DLR-CA15-3-Hu-48T |
DL Develop |
48T |
EUR 574.8 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Carbohydrate Antigen 15-3 (CA15-3) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit |
DLR-CA15-3-Hu-96T |
DL Develop |
96T |
EUR 745.2 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Carbohydrate Antigen 15-3 (CA15-3) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit |
RDR-CA15-3-Hu-48Tests |
Reddot Biotech |
48 Tests |
EUR 600 |
Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit |
RDR-CA15-3-Hu-96Tests |
Reddot Biotech |
96 Tests |
EUR 830.4 |
Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit |
RD-CA15-3-Hu-48Tests |
Reddot Biotech |
48 Tests |
EUR 573.6 |
Human Carbohydrate Antigen 15-3 (CA15-3) ELISA Kit |
RD-CA15-3-Hu-96Tests |
Reddot Biotech |
96 Tests |
EUR 794.4 |
99445-15 DCT 15 X 85MM |
99445-15 |
CORNING |
250/pk |
EUR 116.4 |
Description: Disposable Culture Tubes; DCT's, CGW |
Multiple breast cancer with breast tissue array |
BR087e |
TissueArray |
each |
EUR 48 |
Description: Multiple breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing BR087d |
Breast cancer with matched breast tissue array |
BR251e |
TissueArray |
each |
EUR 60 |
Description: Breast cancer with matched breast tissue array, including pathology grade, IHC info (ER,PR,Her-2,Ki67),TNM\Stage, 6 cases/24 cores (core size 1.5mm), replacing BR251d |
Fluorescent Exosome Standard (Urine ) |
ESF-15 |
Creative Biolabs |
100 µg |
EUR 2067.6 |
Description: Fluorescent exosomes are labeled with green dye, which offer a stable fluorescent labeling. |
Breast cancer tissue array with cancer adjacent breast tissue as control |
BR208a |
TissueArray |
each |
EUR 474 |
Description: Breast cancer tissue array with cancer adjacent breast tissue as control, including TNM, clinical stage and pathology grade, 69 cases/ 207 cores. |
CA 15-3, Human Breast Adenocarcinoma |
P1435-1 |
Biovision |
each |
EUR 130.8 |
CA 15-3, Human Breast Adenocarcinoma |
P1435-5 |
Biovision |
each |
EUR 288 |
Inactivated CMV Grade 3 Antigen |
VAng-Lsx0038-1mg |
Creative Biolabs |
1 mg |
EUR 2503.2 |
Description: CMV Grade 3, natural protein. |
Inactivated MuV Grade 3 Antigen |
VAng-Lsx0411-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: MuV grade 3, native protein. |
Inactivated Rotavirus Grade 3 Antigen |
VAng-Lsx0469-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: Rotavirus Grade 3, native virus. |
Inactivated RuV Grade 3 Antigen |
VAng-Lsx0476-1mL |
Creative Biolabs |
1 mL |
EUR 474 |
Description: RuV Grade 3, natural protein. |
Cancer Antigen 242 Antigen |
VAng-Cr3876-10kU |
Creative Biolabs |
10 kU |
EUR 505.2 |
Description: Cancer Antigen 242 Antigen, Host/Source: Metastatic Liver. The purity is detected by gel filtration. |
Cancer Antigen 50 Antigen |
VAng-Cr3877-50kU |
Creative Biolabs |
50 kU |
EUR 6642 |
Description: Cancer Antigen 50 Antigen, Host/Source: Human Cell Culture. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2. |
Proteinase K, Recombinant, Standard Grade |
9250-100 |
Biovision |
each |
EUR 124.8 |
Proteinase K, Recombinant, Standard Grade |
9250-10G |
Biovision |
each |
EUR 4627.2 |
Proteinase K, Recombinant, Standard Grade |
9250-1G |
Biovision |
each |
EUR 548.4 |
Proteinase K, Recombinant, Standard Grade |
9250-500 |
Biovision |
each |
EUR 314.4 |
Proteinase K, Recombinant, Standard Grade |
9251-100 |
Biovision |
each |
EUR 1266 |
Proteinase K, Recombinant, Standard Grade |
9251-25 |
Biovision |
each |
EUR 352.8 |
Proteinase K, Recombinant, Standard Grade |
9251-5 |
Biovision |
each |
EUR 144 |
Breast cancer (including one case of male breast cancer) with adjacent normal breast tissue array |
BC081120g |
TissueArray |
each |
EUR 306 |
Description: Breast cancer (including one case of male breast cancer) with adjacent normal breast tissue array, including pathology grade, TNM and clinical stage (AJCC 7th edition) with IHC results ER/PR/Her2/Ki67,110 cases/110 cores (core size 1.0 mm), replacing BC081120f |
Breast cancer with adjacent normal breast tissue array |
BR1921c |
TissueArray |
each |
EUR 546 |
Description: Breast cancer with adjacent normal breast tissue array, including pathology grade, TNM, clinical stage and IHC marker (ER, PR and Her-2), 189 cases/192 cores, replacing BR1921b |
Breast disease spectrum (breast cancer progression) tissue array |
BR2082c |
TissueArray |
each |
EUR 546 |
Description: Breast disease spectrum (breast cancer progression) tissue array, including pathology grade, TNM and clinical stage, IHC marker (ER, PR, HER2 and Ki-67), 186 cases/192 cores, replacing BR2082b |
Breast cancer with adjacent normal breast tissue array |
BR803c |
TissueArray |
each |
EUR 258 |
Description: Breast cancer with adjacent normal breast tissue array, including pathology grade, TNM and clinical stage, 80 cases/80 cores, replacing BR803b |
Breast cancer with adjacent normal breast tissue array |
BR901a |
TissueArray |
each |
EUR 270 |
Description: Breast cancer with adjacent normal breast tissue array, including pathology grade, TNM and clinical stage, 45 cases/90 cores, replacing BR901 |
Breast normal tissue with breast cancer tissue array |
BRN801c |
TissueArray |
each |
EUR 270 |
Description: Breast normal tissue with breast cancer tissue array, including pathology grade, TNM and clinical stage, 80 cases/80 cores, replacing BRN801b |
Polystyrene Particle Size Standard |
PPS-3 |
Spherotech |
mL |
EUR 152.4 |
Description: Please reffer to the technical data sheet for more detail information for this item. Our dedicated team would be happy to assist you via live chat, email or phone. |
Breast Cancer Metastasis Suppressor 1 |
PR27265 |
Neuromics |
2 ug |
EUR 229.2 |
Breast cancer test tissue array |
T086e |
TissueArray |
each |
EUR 66 |
Description: Breast cancer test tissue array, including TNM, clinical stage and pathology grade, 12 cases/24 cores, replacing T086d |
Breast Tumor Kinase antibody |
70R-31875 |
Fitzgerald |
100 ug |
EUR 392.4 |
Description: Rabbit polyclonal Breast Tumor Kinase antibody |
Breast Tumor Kinase antibody |
70R-33385 |
Fitzgerald |
100 ug |
EUR 392.4 |
Description: Rabbit polyclonal Breast Tumor Kinase antibody |
Breast Tissue Lysate (Tumor) |
1713-01 |
ProSci |
0.1 mg |
EUR 336.3 |
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Breast Tissue Lysate (Tumor) |
1713-02 |
ProSci |
0.1 mg |
EUR 336.3 |
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Breast Tissue Lysate (Tumor) |
1714-01 |
ProSci |
0.1 mg |
EUR 336.3 |
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Breast Tissue Lysate (Tumor) |
1714-02 |
ProSci |
0.1 mg |
EUR 336.3 |
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Breast Tissue Lysate (Tumor) |
1714-03 |
ProSci |
0.1 mg |
EUR 336.3 |
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Breast Tissue Lysate (Tumor) |
1714-04 |
ProSci |
0.1 mg |
EUR 336.3 |
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Breast Tissue Lysate (Tumor) |
1714-05 |
ProSci |
0.1 mg |
EUR 336.3 |
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Breast Tissue Lysate (Tumor) |
1714-06 |
ProSci |
0.1 mg |
EUR 336.3 |
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Breast Tissue Lysate (Tumor) |
1714-07 |
ProSci |
0.1 mg |
EUR 336.3 |
Description: Breast tumor tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% β-mercaptoethanol. |
Breast Membrane Tumor Lysate |
XBL-10499 |
ProSci |
0.1 mg |
EUR 752.1 |
Description: Human breast tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human breast tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated breast tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated breast tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal. |
Cancer Antigen 72-4 Antigen |
VAng-Cr3878-10kU |
Creative Biolabs |
10 kU |
EUR 505.2 |
Description: Cancer Antigen 72-4 Antigen, Host/Source: Metastatic Liver. The purity is ~65% by SDS-PAGE. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2. |
Advanced stage breast cancer and normal breast tissue array |
BR1191 |
TissueArray |
each |
EUR 306 |
Description: Advanced stage breast cancer and normal breast tissue array, including pathology grade, TNM and clinical stage (AJCC 8.0), ER\PR\HER-2\Ki-67 marker, 119 cases/119 cores, (1.5mm) |
Breast cancer tissue array with adjacent normal breast tissue |
BR8011a |
TissueArray |
each |
EUR 306 |
Description: Breast cancer tissue array with adjacent normal breast tissue, including TNM, clinical stage, pathology grade and DCIS, 80 cases/80 cores, replacing BR8011 |
Breast cancer with matched or unmatched breast tissue array |
BR802c |
TissueArray |
each |
EUR 270 |
Description: Breast cancer with matched or unmatched breast tissue array, including pathology grade, TNM and clinical stage, 53 cases/80 cores, replacing BR802b |
Human CA15-3 Antigen Grade Protein |
abx060972-250kU |
Abbexa |
250 kU |
EUR 2380.8 |
|
Inactivated PIV-3 Grade 2 Antigen |
VAng-Wyb3637-1mL |
Creative Biolabs |
1 mL |
EUR 1363.2 |
Description: Parainfluenza virus type 3 (strain C243) Grade 2, natural antigen |
Inactivated HSV-1 Grade 3 Antigen |
VAng-Lsx0293-1mg |
Creative Biolabs |
1 mg |
EUR 1786.8 |
Description: HSV Type 1 Grade III, native antigen. |
Inactivated HSV-2 Grade 3 Antigen |
VAng-Lsx0302-1mg |
Creative Biolabs |
1 mg |
EUR 1786.8 |
Description: HSV Type 2 Grade III, native antigen. |
Prostate Specific Antigen Std Grade Antigen |
VAng-Cr3891-1mg |
Creative Biolabs |
1 mg |
EUR 604.8 |
Description: Prostate Specific Antigen Std Grade Antigen, Host/Source: Human Seminal Fluid. The purity is detected by salt precipitation. |
CEA Antigen Grade Protein |
abx060976-05mg |
Abbexa |
0.5 mg |
EUR 1161.6 |
|
CEA Antigen Grade Protein |
abx060977-1mg |
Abbexa |
1 mg |
EUR 2030.4 |
|
Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody |
20-abx171475 |
Abbexa |
|
|
|
Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody |
20-abx133658 |
Abbexa |
-
EUR 360.00
-
EUR 526.80
-
EUR 226.80
|
|
|
Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody |
20-abx129227 |
Abbexa |
-
EUR 510.00
-
EUR 159.60
-
EUR 1446.00
-
EUR 693.60
-
EUR 393.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody |
20-abx013807 |
Abbexa |
-
EUR 376.80
-
EUR 117.60
-
EUR 477.60
-
EUR 594.00
|
- 100 ug
- 10 ug
- 200 ug
- 300 µg
|
|
Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody |
abx025588-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody |
abx025588-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody |
20-abx324781 |
Abbexa |
|
|
|
Recombinant Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) |
4-RPG768Hu01 |
Cloud-Clone |
-
EUR 601.69
-
EUR 284.40
-
EUR 1926.34
-
EUR 722.11
-
EUR 1324.22
-
EUR 477.60
-
EUR 4635.84
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Human Breast Cancer Anti-Estrogen Resistance 3 expressed in: E.coli |
9998 SCREW CAP 415/15 |
9998-15 |
CORNING |
288/pk |
EUR 237.6 |
Description: General Apparatus; Stoppers |
Breast Cancer and 8 types of tumor (middle advanced stage)tissue array |
BR20838a |
TissueArray |
each |
EUR 474 |
Description: Breast Cancer and 8 types of tumor (middle advanced stage)tissue array, including pathology grade, TNM/stage with IHC Her-2 results, 118 cases/208 cores (core size 1.5mm), replacing BR20838 |
Breast Cancer Metastasis Suppressor 1 Protein |
20-abx263402 |
Abbexa |
-
EUR 1930.80
-
EUR 393.60
-
EUR 276.00
|
|
|
Autobioluminescent Human Breast Cancer Cells (MCF7) |
ASE-5903 |
Applied StemCell |
1 ml |
EUR 2490 |
Description: 6 month |
Autobioluminescent Human Breast Cancer Cells (T47D) |
ASE-5904 |
Applied StemCell |
1 ml |
EUR 2490 |
Description: 6 month |
Human Breast Cancer Signaling Primer Library |
HBRCA-I |
Real Time Primers |
1 set |
EUR 657.6 |
Breast Cancer Anti-Estrogen Resistance 1 |
PR27245 |
Neuromics |
2 ug |
EUR 229.2 |
anti-Breast cancer suppressor candidate 1 |
YF-PA24096 |
Abfrontier |
50 ul |
EUR 400.8 |
Description: Mouse polyclonal to Breast cancer suppressor candidate 1 |
anti-Breast cancer suppressor candidate 1 |
YF-PA12974 |
Abfrontier |
50 ul |
EUR 435.6 |
Description: Mouse polyclonal to Breast cancer suppressor candidate 1 |
anti-Breast cancer suppressor candidate 1 |
YF-PA12975 |
Abfrontier |
50 ug |
EUR 435.6 |
Description: Mouse polyclonal to Breast cancer suppressor candidate 1 |
Multiple types breast cancer tissue array |
BR1003a |
TissueArray |
each |
EUR 306 |
Description: Multiple types breast cancer tissue array, including pathology grade, TNM and clinical stage, 47 cases/101 cores, replacing BR1003 |
Late stage breast cancer tissue array |
BR1922 |
TissueArray |
each |
EUR 546 |
Description: Late stage breast cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases/192 cores |
Poorly differentiated breast cancer tissue array |
BR351a |
TissueArray |
each |
EUR 66 |
Description: Poorly differentiated breast cancer tissue array, including TNM, clinical stage and pathology grade, 35 cases/35 cores, replacing BR351 |
Breast cancer and normal tissue array |
BR485 |
TissueArray |
each |
EUR 414 |
Description: Breast cancer and normal tissue array, including TNM and pathology grade, 2 serial sections, 48 cases/96 cores |
High-density breast cancer tissue array |
BR6161 |
TissueArray |
each |
EUR 954 |
Description: High-density breast cancer tissue array, with stage, grade and normal breast tissue, 322 cases/616 cores |
Breast cancer and normal tissue array |
BR8014 |
TissueArray |
each |
EUR 306 |
Description: Breast cancer and normal tissue array, including TNM, clinical stage and pathology grade, 40 cases/80 cores, replaced by BR8015 |
Breast tumor tissue array (3 of 5) |
BR20834a |
TissueArray |
each |
EUR 546 |
Description: Breast tumor tissue array (3 of 5), including pathology grade, TNM and clinical stage, 208 cases/208 cores, replacing BR20834 |
Breast Tumor Tissue Array - 16 cases of breast cancer, each in duplicates, paired with adjacent normal tissues |
Z7020007 |
Biochain |
5 slides |
EUR 1657.2 |
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
Breast cancer with matched metastatic carcinoma or breast tissue array |
BRM961a |
TissueArray |
each |
EUR 384 |
Description: Breast cancer with matched metastatic carcinoma or breast tissue array, including pathology grade, TNM, clinical stage and IHC marker (ER, PR and Her-2), 49 cases/96 cores |
Human Cancer Antigen CA15-3 Protein |
abx060965-50kU |
Abbexa |
50 kU |
EUR 3150 |
|
Breast Tumor Kinase Blocking Peptide |
AF4768-BP |
Affbiotech |
1mg |
EUR 234 |
Breast Tumor Kinase antibody (Tyr447) |
70R-33384 |
Fitzgerald |
100 ug |
EUR 392.4 |
Description: Rabbit polyclonal Breast Tumor Kinase antibody (Tyr447) |
Anti-Rabbit Whole Serum | GWS-15 |
GWS-15 |
Immunology Consultants Laboratory |
1.0 mL |
EUR 130 |
Description: Anti-Rabbit Whole Serum | GWS-15 | Immunology Consultants Laboratory Host: Goat Format: Whole Serum Product Type: Primary Antibody Antibody Clonality: Polyclonal |
Liquid Wicks, Size 15, 200 /pk |
W-15 |
MiTeGen |
200 WICKS |
EUR 22 |
|
Description: Liquid Wicks, Size 15, 200 /pk |
Cancer Antigen 125 Antigen (Human Adenocarcinoma) |
VAng-Cr3868-10kU |
Creative Biolabs |
10 kU |
EUR 505.2 |
Description: Cancer Antigen 125 Antigen, Host/Source: Human Adenocarcinoma. The purity is detected by salt extraction and chromatography. |
Cancer Antigen 125 Antigen (Ascites Fluid) |
VAng-Cr3870-10kU |
Creative Biolabs |
10 kU |
EUR 1132.8 |
Description: Cancer Antigen 125 Antigen, Host/Source: Ascites Fluid. The purity is ≥ 95% by SDS-PAGE. |
Direct alteration of extracellular cues through in situ matrix softening reversed YAP exercise and the epigenetic program. Our findings recommend that epigenetic reprogramming of the mechanophysical properties of the extracellular microenvironment of stable tumours might symbolize a therapeutic technique for the inhibition of most cancers development.